top of page
  • Active, not recruiting

NCT02963493: Phase 2 - Melphalan Flufenamide (Melflufen) With Dexamethasone in Relapsed MM (HORIZON)

Updated: Jun 21, 2022


A Study of Melphalan Flufenamide (Melflufen) in Combination With Dexamethasone in Relapsed Refractory Multiple Myeloma Patients (HORIZON)

Horizon trial - Melphalan Flufenamide (Melflufen)

This study will evaluate melflufen in combination with dexamethasone in the treatment of relapsed refractory multiple myeloma in adult patients with disease refractory to pomalidomide and/or an anti-CD38 monoclonal antibody. All patients in the study will be treated with melflufen on Day 1 and dexamethasone on Days 1, 8, 15 and 22 of each 28-day cycle.


Oncopeptides AB


Precision For Medicine

Multiple locations

International Study Identifier: NCT02963493

Official Title: A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination With Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody

First Posted : November 15, 2016

Click here to see details on



Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma

PMID: 33296242; J Clin Oncol; March 2021

Click here to see details


* Dexamethasone (Decadron)

* Melphalan Flufenamide (Melflufen) Pepaxto


- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston

- New York: Memorial Sloan-Kettering Cancer Center New York

- Texas: Baylor University Medical Center Dallas



United States, California

United States, Florida

United States, Illinois

United States, Massachusetts

United States, Michigan

United States, New York

United States, Pennsylvania

United States, Texas






Posts Archive
bottom of page